UNSPSC 51294522: Paroxetine maleate

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C19H20FNO3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F726G2563Q, chemically known as (3s,4r)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-piperidine maleate, but more generally known as paroxetine maleate, which bears US NIH Compound Identifier 6435921.

European Medicines Agency schedules paroxetine maleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09631MIG. Most nations, for tariff purposes, schedule paroxetine maleate under HS 29349990. SMILES: C1CC(CCC1[C@@H]2CCNC[C@H]2COC3CCC4C(C3)OCO4)F.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51294522 Paroxetine maleate is a Commodity code that, based on recent state and local procurement activity, actually encompasses a broad range of pharmaceutical products—generic pharmaceuticals, over-the-counter drugs, and emergency medications—rather than paroxetine specifically. State and local governments use this code family to solicit everything from naloxone and drug-deactivation systems for public health initiatives to multi-source generic pharmaceuticals and OTC products distributed across state and local healthcare facilities. Issuing bodies include county health departments (such as Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The competitive landscape spans manufacturers required to maintain FDA compliance, cGMP certification, and Drug Supply Chain Security Act adherence, with vendors typically obligated to work through established wholesaler networks and maintain substantial commercial general liability and professional liability insurance.

Recent opportunities reflect two distinct procurement models. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with a July 1, 2026 effective date, establishing statewide contracts across multiple participating jurisdictions including Oregon and requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson). Seminole County, Florida issued an IFB in June 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries, reflecting county-level procurement for community health support. The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs outside traditional PBM and GPO relationships, signaling state interest in alternative supply-chain models. Recent activity concentrates in the upper Midwest and Southeast, with multistate cooperative purchasing driving broader geographic reach.